BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21045706)

  • 21. Benign prostatic hyperplasia--review of treatment options.
    Oehlke KJ; Branaugh ML
    S D Med; 2009 May; 62(5):202-3. PubMed ID: 19489345
    [No Abstract]   [Full Text] [Related]  

  • 22. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
    Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
    J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions.
    Parsons JK; Sarma AV; McVary K; Wei JT
    J Urol; 2009 Dec; 182(6 Suppl):S27-31. PubMed ID: 19846130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice.
    Yassin A; Saad F; Hoesl CE; Traish AM; Hammadeh M; Shabsigh R
    Andrologia; 2006 Feb; 38(1):1-12. PubMed ID: 16420236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk.
    Emberton M; Zinner N; Michel MC; Gittelman M; Chung MK; Madersbacher S
    BJU Int; 2007 Aug; 100(2):249-53. PubMed ID: 17617135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Djavan B; Chapple C; Milani S; Marberger M
    Urology; 2004 Dec; 64(6):1081-8. PubMed ID: 15596173
    [No Abstract]   [Full Text] [Related]  

  • 27. Sexual Side Effects of Medical and Surgical Benign Prostatic Hyperplasia Treatments.
    Welliver C; Essa A
    Urol Clin North Am; 2016 Aug; 43(3):393-404. PubMed ID: 27476132
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of alpha-adrenoreceptors in the treatment of urological diseases.
    Romics I
    Neurochem Int; 2007 Oct; 51(5):328-31. PubMed ID: 17688972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function.
    Lowe FC
    BJU Int; 2005 Jun; 95 Suppl 4():12-8. PubMed ID: 15871731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostatic and extraprostatic alpha-adrenoceptors--contributions to the lower urinary tract symptoms in benign prostatic hyperplasia.
    Andersson KE
    Scand J Urol Nephrol Suppl; 1996; 179():105-11. PubMed ID: 8908675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transurethral resection of the prostate: failure patterns and surgical outcomes in patients with symptoms refractory to alpha-antagonists.
    Blanchard K; Hananel A; Rutchik S; Sullivan J
    South Med J; 2000 Dec; 93(12):1192-6. PubMed ID: 11142455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. (Arylpiperazinyl)cyclohexylsufonamides: discovery of alpha(1a/1d)-selective adrenergic receptor antagonists for the treatment of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms (BPH/LUTS).
    Chiu G; Li S; Connolly PJ; Pulito V; Liu J; Middleton SA
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3292-7. PubMed ID: 17452102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concordance rates and modifiable risk factors for lower urinary tract symptoms in twins.
    Rohrmann S; Fallin MD; Page WF; Reed T; Partin AW; Walsh PC; Platz EA
    Epidemiology; 2006 Jul; 17(4):419-27. PubMed ID: 16699472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications.
    Seftel A; Rosen R; Kuritzky L
    Int J Impot Res; 2007; 19(4):386-92. PubMed ID: 17377613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Managing enlarged prostate in primary care.
    Naslund MJ; Costa FJ; Miner MM
    Int J Clin Pract; 2006 Dec; 60(12):1609-15. PubMed ID: 17109668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Under what conditions is feedback microwave thermotherapy (ProstaLund Feedback Treatment) cost-effective in comparison with alpha-blockade in the treatment of benign prostatic hyperplasia and lower urinary tract symptoms?
    Ragnarson Tennvall G; Hjelmgren J; Malmberg L
    Scand J Urol Nephrol; 2006; 40(6):495-505. PubMed ID: 17130102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Managing patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    McNaughton-Collins M; Barry MJ
    Am J Med; 2005 Dec; 118(12):1331-9. PubMed ID: 16378773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems.
    Parsons JK
    J Urol; 2007 Aug; 178(2):395-401. PubMed ID: 17561143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benign prostatic hyperplasia in older men.
    Gerber GS
    Clin Geriatr Med; 1998 May; 14(2):317-31. PubMed ID: 9536108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on the relationship between sexual dysfunction and lower urinary tract symptoms/benign prostatic hyperplasia.
    Rosen RC
    Curr Opin Urol; 2006 Jan; 16(1):11-9. PubMed ID: 16385195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.